AbbVie (ABBV) Stock

AbbVie (NYSE: ABBV) has just announced its Q4 results, showing revenues and earnings that exceeded expectations. The company reported sales of $15.1 billion and adjusted earnings of $2.16 per share, while analysts had predicted $14.8 billion in sales and $2.11 in earnings.

The economy is a mix, with some areas doing well and others struggling. I believe cyclical stocks and healthcare have potential for growth, even though they are currently underperforming. One stock has a strong chance of recovery, while the other is a high-yield healthcare option that can withstand economic downturns, making both good choices for balancing risk and reward in today's unpredictable market.

A lot of individuals aim to save $1 million for their retirement. While this sum might not be enough in the current economy, it is still a solid beginning.

At midday, U.S. stocks were generally up due to good news from tech companies and a report indicating that December's inflation was in line with expectations.

AbbVie's earnings for the fourth quarter and the entire year of 2024 exceeded expectations, thanks to the strong sales of Skyrizi and Rinvoq, even though Humira's revenue fell due to patent expirations. The management is optimistic about the future, predicting high single-digit revenue growth until 2029, with Skyrizi and Rinvoq expected to bring in $31 billion in sales by 2027. Although AbbVie's mergers and acquisitions strategy faced challenges, particularly with the Cerevel deal, the company is still hopeful about upcoming approvals and growth in oncology and neuroscience.

AbbVie Inc. announced impressive results for the fourth quarter of 2024, mainly due to the success of Skyrizi, Rinvoq, neuroscience products, and eye care, which helped counterbalance the disappointing performance of Humira. For 2025, the company forecasts $59 billion in revenue and an adjusted earnings per share of $12.12 to $12.32, although they anticipate challenges with Humira and changes to the Medicare Part D program. Management predicts a high single-digit revenue growth until 2029, as there are no significant products expected to lose exclusivity during this time.

ABBV's earnings and sales for the fourth quarter exceeded expectations. The management has increased the 2027 forecast for their new immunology drugs to over $31 billion.

The pre-market activity today is looking good, as futures are up for the main indexes. The Dow has gained 110 points, the S&P 500 is up by 26 points, and the Nasdaq is leading with an increase of 158 points. Additionally, the small-cap Russell 2000 has risen by 5 points.

AbbVie NYSE: ABBV is a strong pharmaceutical company that is known for increasing its dividends and has a positive growth forecast, making it a good time to buy shares. Concerns about the expiration of Humira's patent are fading, as products like Skyrizi and Rinvoq, along with a varied range of offerings, are becoming more popular.